EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 307 filers reported holding EXELIXIS INC in Q4 2017. The put-call ratio across all filers is 0.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,781,993 | -11.5% | 168,313 | -6.5% | 0.02% | -11.8% |
Q1 2024 | $4,272,183 | -6.2% | 180,033 | -5.2% | 0.02% | -5.6% |
Q4 2023 | $4,553,950 | -3.9% | 189,827 | -12.5% | 0.02% | -14.3% |
Q3 2023 | $4,741,000 | +7.2% | 216,989 | -6.2% | 0.02% | +16.7% |
Q2 2023 | $4,423,000 | -7.1% | 231,428 | -5.7% | 0.02% | -10.0% |
Q1 2023 | $4,761,000 | +19.7% | 245,300 | -1.1% | 0.02% | +17.6% |
Q4 2022 | $3,979,000 | +23.2% | 248,043 | +20.4% | 0.02% | +13.3% |
Q3 2022 | $3,230,000 | -19.9% | 205,964 | +6.3% | 0.02% | -11.8% |
Q2 2022 | $4,032,000 | -9.6% | 193,679 | -1.5% | 0.02% | +6.2% |
Q1 2022 | $4,459,000 | +21.1% | 196,692 | -2.3% | 0.02% | +33.3% |
Q4 2021 | $3,681,000 | -7.3% | 201,370 | +7.2% | 0.01% | -14.3% |
Q3 2021 | $3,972,000 | +22.2% | 187,902 | +5.3% | 0.01% | +27.3% |
Q2 2021 | $3,251,000 | -12.3% | 178,449 | +8.8% | 0.01% | -26.7% |
Q1 2021 | $3,706,000 | +22.3% | 164,033 | +8.6% | 0.02% | +7.1% |
Q4 2020 | $3,031,000 | +2.9% | 151,035 | +25.4% | 0.01% | -12.5% |
Q3 2020 | $2,945,000 | -38.1% | 120,453 | -39.9% | 0.02% | -40.7% |
Q2 2020 | $4,755,000 | +77.9% | 200,311 | +29.0% | 0.03% | +50.0% |
Q1 2020 | $2,673,000 | -23.3% | 155,252 | -21.5% | 0.02% | 0.0% |
Q4 2019 | $3,486,000 | -8.3% | 197,825 | -8.0% | 0.02% | -10.0% |
Q3 2019 | $3,803,000 | -15.0% | 215,062 | +2.7% | 0.02% | -16.7% |
Q2 2019 | $4,475,000 | -12.6% | 209,427 | -2.6% | 0.02% | -11.1% |
Q1 2019 | $5,119,000 | -1.2% | 215,073 | -18.4% | 0.03% | -10.0% |
Q4 2018 | $5,183,000 | +118.7% | 263,514 | +97.0% | 0.03% | +150.0% |
Q3 2018 | $2,370,000 | -8.1% | 133,765 | +11.6% | 0.01% | -7.7% |
Q2 2018 | $2,580,000 | -29.7% | 119,888 | -27.6% | 0.01% | -31.6% |
Q1 2018 | $3,670,000 | -3.7% | 165,687 | +32.2% | 0.02% | 0.0% |
Q4 2017 | $3,811,000 | +25.7% | 125,361 | +0.2% | 0.02% | +18.8% |
Q3 2017 | $3,032,000 | -73.6% | 125,146 | -73.2% | 0.02% | -50.0% |
Q2 2017 | $11,494,000 | +408.6% | 466,644 | +347.3% | 0.03% | +146.2% |
Q1 2017 | $2,260,000 | -4.2% | 104,314 | 0.0% | 0.01% | 0.0% |
Q4 2016 | $2,360,000 | – | 104,314 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |